<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03673748</url>
  </required_header>
  <id_info>
    <org_study_id>TerCel_006</org_study_id>
    <secondary_id>2017-000391-28</secondary_id>
    <nct_id>NCT03673748</nct_id>
  </id_info>
  <brief_title>Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells</brief_title>
  <acronym>MSV_LE</acronym>
  <official_title>A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital del Río Hortega</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clínico Universitario de Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells
      (MSCs) obtained from bone marrow for the treatment of adults with active proliferative lupus
      nephritis. The objective of this study is to evaluate the efficacy of mesenchymal stem cells
      (MSCs) in achieving a full response in the treatment of Lupus Nephritis (LN) during its
      induction period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2b, double-blind (neither the participant nor the investigator will know if active
      drug or placebo is assigned), placebo-controlled, randomized (assigned by chance), in which
      subjects with Lupus Nephritis (LN), who do not respond -or respond partially- to induction
      treatment, shall receive either MSCs (1.5 million cells/Kg) or placebo by intravenous
      injection. The administration of cells will be done only once. Eligible patients should have
      been receiving induction treatment for at least three months but no more than six.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Control arm (placebo) and experimental arm (mesenchymal stromal cells)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Both experimental and Control will receive a similar endovenous injection with either cells or placebo. Blind to participant, investigator ans care providers,</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of severe adverse events</measure>
    <time_frame>0-52 weeks</time_frame>
    <description>Frequency of grade 3 or higher adverse events (SAEs) at or prior to Week 52</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of Complete Renal Response defined as decrease of urine protein:creatinine ratio (UPCR; Normal value&lt;50mg/mmol)</measure>
    <time_frame>0-52 weeks</time_frame>
    <description>Evaluates the efficacy of mesenchymal stem cells (MSCs) in achieving full or partial response of proliferative Lupus. The UPCR normal value is &lt;50mg/mmol (roughly equivalent to proteinuria &lt;0.5g/24h). Partial renal response, defined as ≥50% reduction in proteinuria should be achieved preferably by 6 months and no later than 12 months following treatment initiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in disease activity measured by change of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K)</measure>
    <time_frame>0-52 wk</time_frame>
    <description>SLEDAI measures activity by computing the score of 24 parameters. Range: 0 to 105.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prednisone dose measured as percent of the baseline value</measure>
    <time_frame>0-52 wk</time_frame>
    <description>Decrease of activity permits to decrease medication. Units are percent value of baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular markers of inflammation and autoimmunity</measure>
    <time_frame>0-52 wk</time_frame>
    <description>Lymphocyte profiles, CD3, CD19, CD16+CD56,CD4/CD8, Tregs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum markers of inflammation and autoimmunity</measure>
    <time_frame>0-52 wk</time_frame>
    <description>Anti-DNA antibodies, complement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Lupus Nephritis</condition>
  <condition>Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stromal cells (MSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 1.5 million cells per kg wt suspended in isotonic medium (Physiological saline solution + 1% Human Albumin + 5 mM Glucose). All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a placebo infusion that does not contain any mesenchymal stem cells. The placebo infusion will consist of physiological saline solution + 1% Human Albumin + 5 mM Glucose, which is the same vehicle used to deliver the MSCs in the experimental groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesenchymal stromal cells (MSC)</intervention_name>
    <description>Endovenous injection of MSV in saline</description>
    <arm_group_label>Mesenchymal stromal cells (MSC)</arm_group_label>
    <other_name>MSV, GMP-compliant MSC manufactured by IBGM in Valladolid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Endovenous injection of saline without cells</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 yrs with written informed consent.

          -  SLE diagnosis fulfilling at least 4 out of the 11 ACR criteria during the course of
             their illness.

          -  Diagnosis of LN class (2003 classification by International Society of
             Nephrology/Renal Pathology Society) by biopsy less than 6 months prior.

          -  No response or partial response to induction therapy, according the recommendations of
             EULAR/ERA-EDTA and ACR with corticoids plus or not cyclophosphamide (500-1.000 mg/m²
             body surface/m²) or mycophenolate mofetil (2-2.5 gr/day) or mycophenolate sodium
             (1.040-1.800 mg/day), after at least three months.

          -  SLEDAI-2K score ≥ 6 at selection period.

          -  Women subjects of childbearing potential must use a highly effective method of
             contraception to prevent pregnancy.

          -  History of vaccinations against S. pneumococcus, H. influenza and seasonal
             vaccinations, as required.

        Exclusion Criteria:

          -  Use of corticoids, mycophenolate, cyclophosphamide above doses permitted for
             induction, according to the EULAR/ERA-EDTA and ACR.

          -  Use of rituximab, belimumab or ocrelizumab, or other B cell-directed biologic
             therapies within 1 yr before treatment.

          -  Use of abatacept within 1 yr before treatment.

          -  Use of any tumor necrosis factor (TNF) inhibitor therapy within 1 yr before selection.

          -  Use of immunoglobulin treatment within 1 yr before treatment.

          -  Change in dosage of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin
             receptor blocker (ARB) within 2 months before treatment.

          -  Treatment with other investigational agents within the last 3 months or 5 half-lives
             prior to treatment.

          -  Any condition that in the investigator´s opinion constitutes an unnecessary risk or a
             counterindication for participation.

          -  History of or planned renal or other organ transplant.

          -  Positive human immunodeficiency virus or hepatitis C Ab and/or PCR, or hepatitis B
             surface antigen (+), or hepatitis B cIgG and/or IgM Ab(+) with (-) hepatitis B sAb.

          -  Diagnosis of active tuberculosis, or latent tuberculosis infection.

          -  History of cancer.

          -  History of major surgery within 6 months prior to treatment.

          -  Lactating women.

          -  Legal incapacity or limited legal capacity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Barbado, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Río Hortega, Valladolid, Spain,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Barbado, MD, PhD</last_name>
    <phone>+34 983 420400</phone>
    <email>jbarbadoa@saludcastillayleon.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Javier Garcia-Sancho, MD, PhD</last_name>
    <phone>+34 983 184827</phone>
    <email>jgsancho@ibgm.uva.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Río Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Julia Barbado, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://ghr.nlm.nih.gov/condition/systemic-lupus-erythematosus</url>
    <description>SLE</description>
  </link>
  <link>
    <url>https://medlineplus.gov/lupus.html</url>
    <description>Lupus</description>
  </link>
  <results_reference>
    <citation>Vega A, Martín-Ferrero MA, Del Canto F, Alberca M, García V, Munar A, Orozco L, Soler R, Fuertes JJ, Huguet M, Sánchez A, García-Sancho J. Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial. Transplantation. 2015 Aug;99(8):1681-90. doi: 10.1097/TP.0000000000000678.</citation>
    <PMID>25822648</PMID>
  </results_reference>
  <results_reference>
    <citation>Noriega DC, Ardura F, Hernández-Ramajo R, Martín-Ferrero MÁ, Sánchez-Lite I, Toribio B, Alberca M, García V, Moraleda JM, Sánchez A, García-Sancho J. Intervertebral Disc Repair by Allogeneic Mesenchymal Bone Marrow Cells: A Randomized Controlled Trial. Transplantation. 2017 Aug;101(8):1945-1951. doi: 10.1097/TP.0000000000001484.</citation>
    <PMID>27661661</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus Erythematosus</keyword>
  <keyword>Lupus Nephritis</keyword>
  <keyword>Stem Cell</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Autoimmune diseases</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

